Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangke powder
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Yangke powder (yǎng ké sǎn-YKS) is a Traditional Chinese Medicine (TCM) formula that has demonstrated potential in alleviating asthma symptoms and reducing its acute exacerbation. It works by inhibiting the PI3K/AKT/NF-κB signaling pathway, which leads to improved airway resistance, reduced inflammation, decreased mucus production, and attenuated airway remodeling. The formula also reduces Th2 cytokines and IgE levels. Key active ingredients identified in Yangke powder include Kaempferol, Norephedrine, Cynaroside, Genistein, and Rutin, which impact biomarkers such as AKT1, TNF, and IL1B.
- Other names
- yǎng ké sǎn
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Yangke powder.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yangke powder.